A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (NCT05169515)

🧪 Interventions in This Study

• SC Mosunetuzumab (DRUG)
• IV Glofitamab (DRUG)
• Iberdomide (DRUG)
• Golcadomide (DRUG)
• Obinutuzumab (DRUG)
• Tocilizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (25 Sites)

• UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program — San Francisco, California
• University of Colorado — Aurora, Colorado
• Moffitt Cancer Center — Tampa, Florida
• The University of Chicago — Chicago, Illinois
• Levine Cancer Institute — Charlotte, North Carolina
• UT MD Anderson Cancer Center — Houston, Texas
• Soroka — Beersheba,
• Rambam Health Care Campus — Haifa,
• Hadassah University Hospital - Ein Kerem — Jerusalem,
• Center Hospital — Ramat Gan,
• Sourasky Medical Center — Tel Aviv,
• IRCCS Azienda Ospedaliero Universitaria di Bologna — Bologna, Emilia-Romagna
• IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori" — Meldola, Emilia-Romagna
• Irccs Ospedale San Raffaele — Milan, Lombardy
• Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chia — Pisa, Piedmont
• ICO L'Hospitalet — L'Hospitalet de Llobregat, Barcelona
• Hospital Universitario La Fe — Valencia, Valencia
• Hospital Universitari Vall d Hebron — Barcelona,
• Clinica Universidad de Navarra-Madrid — Madrid,
• Hospital General Universitario Gregorio Maranon — Madrid,
• Hosp Universitario Salamanca — Salamanca,
• NHS Greater Glasgow and Clyde — Glasgow,
• University College London Hospitals — London,
• Nottingham University Hospitals City Campus — Nottingham,
• Oxford University Hospitals NHS Trust - Churchill Hospital — Oxford,

📞 Contact the Study Coordinator

Phone: (877) 827-3222

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-Hodgkin Lymphoma

• A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma — Duarte, California
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma — Tucson, Arizona
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies — Mobile, Alabama
• AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma — St Louis, Missouri
• Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma — Chicago, Illinois
• Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy — St Louis, Missouri

Explore by condition: All Non-Hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.